REG - Nuformix PLC - Notice of Allowance of NXP002 Patent in Japan

NuformixAnnouncement

23/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231023:nRSW8813Qa&default-theme=true

RNS Number : 8813Q  Nuformix PLC  23 October 2023

23 October 2023

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Notice of Allowance of NXP002 Patent in Japan

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that it has been issued with an Official Decision to Grant Notice of
Allowance for Japanese National Phase Patent Application No. 2020-555115
entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".

 

NXP002 is the Company's lead asset and a potential novel inhaled treatment for
Idiopathic Pulmonary Fibrosis ("IPF"). The granted patent describes a
proprietary new form of the drug tranilast, uniquely enabling delivery via an
inhaled nebulised formulation. Nuformix owns two patent applications relating
to crystalline forms of tranilast, one of which had already been granted
globally. This second patent application, which as has already been granted in
the US, specifically addresses the novel tranilast forms being progressed by
the Company as a potential novel IPF treatment.

 

Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we have
received this Official Decision to Grant from the Japanese Patent Office. This
provides confirmation that no prior art exists in relation to NXP002, which is
very important given that this is the territory in which tranilast was first
invented and where the vast majority of considerable subsequent development
work has been conducted. The grant is therefore an important step forward for
our lead asset NXP002. We expect the European grant to follow shortly, which
will further support the Company's on-going partnering activities."

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZMZGMZMGFZM